Pramodini Medicare IPO Final Day: GMP ₹0

Welcome back, investors! We’ve reached the final day of the Pramodini Medicare NSE SME IPO subscription. As the clock ticks down, it’s time to take a hard look at where we stand. Today marks the closing of the book-building process, and the numbers are… well, they’re certainly telling a story. Let’s dive into the day 3 subscription update and see what it signals for this healthcare venture.

Subscription Status

As of the closing bell on August 14, 2026, the subscription figures for Pramodini Medicare IPO are showing a complete lack of interest across all categories. The Retail, Non-Institutional Investor (NII), and Qualified Institutional Buyer (QIB) segments are all at 0x subscription. This is a rather unusual situation, especially for an SME IPO aiming to raise capital. Typically, even by day 3, you’d expect some level of participation, even if modest. The absence of any subscription across the board suggests that investors are either holding back their decisions until the very last moment, which is unlikely given the closing, or there’s a significant lack of confidence in the issue at its current price band of ₹118 per share. For an SME IPO, seeing zero demand from retail investors, who are usually the first to jump in, is a key indicator to watch. Similarly, the silence from NIIs and QIBs, who often assess the long-term potential and valuation, is quite telling. This could concern potential investors looking for early signs of demand.

GMP Update

Now, let’s talk Grey Market Premium (GMP). Interestingly, the GMP for Pramodini Medicare IPO has remained unchanged at ₹0. Yesterday, it was also at ₹0, and today, on the closing day, it hasn’t budged. A GMP of ₹0 indicates that the market isn’t currently pricing in any premium over the issue price of ₹118. In fact, it suggests that the grey market expects the stock to list exactly at its issue price, if not lower. This lack of positive sentiment in the grey market often mirrors the subscription numbers. When the GMP is stagnant or negative, it usually means that demand is weak, and there’s no speculative interest driving up the perceived listing gains. The bottom line here is that the current GMP isn’t providing any encouraging signals for a strong listing performance.

Should You Apply?

So, the big question: should you have applied for Pramodini Medicare’s IPO? Based on the data available on this closing day, it’s a tough call. The subscription numbers are exceptionally low, with zero interest reported across all categories. Coupled with a GMP of ₹0, which suggests no immediate listing gains are anticipated, the picture isn’t exactly rosy. The issue price is ₹118, and the expected listing price is also around ₹118, with no premium indicated by the GMP. While a lack of oversubscription doesn’t automatically mean a bad investment, it does signal a lack of immediate investor enthusiasm. For those who were considering this IPO for quick listing gains, the current scenario doesn’t support that objective. However, for investors with a long-term perspective who believe in the fundamental business of Pramodini Medicare, the low subscription might present an opportunity to enter at the issue price without the pressure of an oversubscribed IPO. As always, remember that this is not financial advice. It’s always a good idea to consult with your SEBI registered investment advisor before making any investment decisions. You can view full Pramodini Medicare IPO details on our site for further information.